Contact Congress about S. 2761: RESULTS Act
Medicare would use a large private claims database to help set prices for many common lab tests. The bill also limits how fast some payments can fall and adds backup rules when data are missing.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
RESULTS Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.
Latest action on S. 2761: Read twice and referred to the Committee on Finance.
Who this affects: This bill mainly affects labs that bill Medicare for diagnostic tests, especially labs that offer common non-advanced tests. It also affects Medicare officials who set payment rates and the private claims data group that would supply price information. Patients could feel the effects if payment changes alter which tests labs offer or how easy tests are to get.
Why this matters: Medicare's lab test prices can affect which tests labs offer and how easy patients can get them. This bill tries to tie those prices more closely to broad private insurance data. It also tries to avoid sharp payment drops when data are missing or rates fall quickly. The actual effect on Medicare spending, lab finances, and patient access would depend on how the rules are carried out.
Key provisions in S. 2761
- Starting with data collected for reporting periods that begin January 1, 2028, Health and Human Services must get price and volume data from a qualifying claims data group. This applies to widely available non-advanced lab tests.
- The claims database must be very large and checked for accuracy. It must include at least 50 billion validated claims from more than 50 private payors, cover all states and Washington, D.C., and follow HIPAA and other privacy laws.
- Starting with 2028 reporting periods, the bill changes which labs count as applicable laboratories, meaning labs that must report data. It uses the definition in 42 C.F.R. 414.502 as of May 1, 2025, but leaves out one paragraph.
- The bill creates two groups of non-advanced diagnostic lab tests: widely available and non-widely available. A test is usually widely available if more than 100 different Medicare providers or suppliers were paid for it during a recent 6-month period.
- Only settled private insurance payments would count as final payment rates. Medicare would leave out denied claims, appealed payments, payments later taken back, and errors when setting market-based lab fees.
How Modern Action helps you take action on S. 2761
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Questions people ask about S. 2761
- What is S. 2761?
- Medicare would use a large private claims database to help set prices for many common lab tests. The bill also limits how fast some payments can fall and adds backup rules when data are missing.
- How do I support or oppose S. 2761?
- Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
- Who should I contact about S. 2761?
- Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
- Can Modern Action explain S. 2761 before I act?
- Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.
